Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, Japanese Phase III trial in 526 patients, 10 and 20 mg doses of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury